Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$171.97
pos +0.00
+0.00%
Today's Range: 169.77 - 172.99 | AMGN Avg Daily Volume: 2,907,900
Last Update: 08/26/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 5.94%
Open: $0.00
Previous Close: $170.23
52 Week Range: $130.09 - $176.64
Oustanding Shares: 748,360,906
Market Cap: 127,393,477,028
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 2 2 2
Hold 9 10 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.32 2.34 2.30 2.30
Latest Dividend: 1.00
Latest Dividend Yield: 2.35%
Dividend Ex-Date: 08/15/16
Price Earnings Ratio: 15.35
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
15.35 18.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.56% 11.68% 51.18%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $2.80 $2.81 $11.35 $12.26
Number of Analysts 11 9 12 12
High Estimate $3.12 $3.12 $11.98 $13.52
Low Estimate $2.58 $2.64 $11.10 $11.40
Prior Year $2.72 $2.61 $10.38 $11.35
Growth Rate (Year over Year) 2.87% 7.62% 9.35% 7.97%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Aug 22, 2016 | 10:31 AM EDT
Las Vegas Sands (LVS) continues to show strength after Bank of America/Merrill Lynch put out an optimistic note this morning about Macau gambling. Energy is weak in early trading. Oil has drifted back down to around $47 a barrel following its recent roughly 20% rally.
By

James Passeri

 | Aug 18, 2016 | 11:55 AM EDT

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

By

Bret Jensen

 | Aug 11, 2016 | 12:00 PM EDT
These are the biggest errors that I've made over the years.
By

Bret Jensen

 | Aug 4, 2016 | 12:04 PM EDT
These sectors offer value as the S&P 500 trades at 19x earnings.
By

James Passeri

 | Aug 2, 2016 | 4:28 PM EDT
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
By

Bret Jensen

 | Aug 2, 2016 | 11:00 AM EDT
The sector seems to be rebounding after tumbling by more than 40%.
By

Bruce Kamich

 | Aug 1, 2016 | 4:04 PM EDT
The company has pushed to the top of a large consolidation pattern.
By

Bret Jensen

 | Aug 1, 2016 | 1:00 PM EDT
The bifurcation can be seen just by looking at Apple's recent results.
By

Jim Cramer

 | Aug 1, 2016 | 12:07 PM EDT
That may be the best way to get through the notorious month of August.

bullishAmgen estimates, target increased at BMO

Jul 28, 2016 | 7:16 AM EDT
AMGN estimates were raised through 2017, BMO Capital said. Company has strong operating momentum. Outperform rating and new $190 price target.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.